A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors

SYHA1813 is a potent multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs)/colony-stimulating factor 1 receptor (CSF1R). This study aimed to evaluate the safety, pharmacokinetics (PK), and antitumor activity of escalating doses of SYHA1813 in patients with recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Zhuang, Li, Shenglan, Lin, Yi, Li, Yongsheng, Mao, Ying, Zhang, Jing, Lei, Ting, Wang, Haidan, Su, Yangzhi, Yang, Yang, Qiu, Jingbo, Li, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140125/
https://www.ncbi.nlm.nih.gov/pubmed/36884148
http://dx.doi.org/10.1007/s10637-022-01325-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140125/
https://www.ncbi.nlm.nih.gov/pubmed/36884148
http://dx.doi.org/10.1007/s10637-022-01325-4

Ejemplares similares